Phase 1
๐ Investigational Drug / Biologic
NCT05204862
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
๐ NEXT Oncology โ San Antonio, Texas
View Study & Screener โ